genesis in vivo in man, however, is still a matter of controversy ( 5 , 11). This paper presents evidence for a much reduced An infant with a of h~~o g l~c e m i a suffered from g l~c o n e~g e n~s i s in an infant with hyperinsulinism, The hypoglyh~~o g l~c e m i a caused h~~erinsulinism. G1ucagon se-cemia was best counteracted by injections of long acting glucacretion was normal. The in vivo incorporation of 14C from gon. alanine into glucose was much reduced, but the key gluconeogenic enzymes revealed normal to high activities in vitro, with normal intracellular distributions. The glucogenic amino acids in CASE REPORT plasma tended to be high, especially proline. A n alanine load revealed a normal glucagon secretion pattern, whereas the BRB, a boy, was born at term On February 16, l Y 7 j , after a insulin secretion was inappropriately strong. The insulin re-normal Pregnancy. Birthweight was 2800 g, length 48 cm, and sponse to glucagon, however, was subnormal. The alanine load the neonatal period was uneventful. b he ~a t i e n t has two sisters, caused a paradoxic drop in plasma pyruvate. Serial determina-One of whom suffered from hypoglycemia from the age of 2 tions of the fasting values of plasma alanine and free fatty acids months. the and the @FA) disclosed a highly significant negative correlation. had suffered from hypoglycemia. The sister and the mother The best therapeutic effect was obtained with long acting recovered s~ontaneously at 4-5 years of age, and are now in glucagon sc twice daily, but hypoglycemia before the next good health, except that the sister is slightly mentally retarded. injection of glucagon could not be avoided. Glucagon treatment Studies of the other members were refused. caused a marked drop in the plasma amino acids, including the The patient first experienced symptoms of hypoglycemia at branched-chained, and a highly significant decrease in plasma 4.5 months of age, when he got attacks with loss of tonus, eyetriglycerides and increase in FFA, whereas glycerol did not rolling, smacking of the lips, and, occasionally, convulsions. H e change. Dipheuylhydantoin caused a significant increase in Was first admitted to our hospital at 7 months of age, with a blood glucose, but therapeutic serum levels of the drug were glucose of 0.83 mmol/liter. Routine laboratory difficult to achieve. investigations were normal, except for moderate elevations of ~~~i~~ glucagon treatment an oral glucose tolerance test was alanine aminotransferase and aspartate aminotransferase in senormal, with a normal increase in insulin, whereas an iv glucose rum. These values later normalized, but intermittently alanine tolerance test was diabetic (KG = 1.0), and there was n o rise in aminotransferase, alkaline phosphatase, and y-glutam~l transinsulin.
Summary
genesis in vivo in man, however, is still a matter of controversy ( 5 , 11) . This paper presents evidence for a much reduced An infant with a of h~~o g l~c e m i a suffered from g l~c o n e~g e n~s i s in an infant with hyperinsulinism, The hypoglyh~~o g l~c e m i a caused h~~erinsulinism. G1ucagon se-cemia was best counteracted by injections of long acting glucacretion was normal. The in vivo incorporation of 14C from gon. alanine into glucose was much reduced, but the key gluconeogenic enzymes revealed normal to high activities in vitro, with normal intracellular distributions. The glucogenic amino acids in CASE REPORT plasma tended to be high, especially proline. A n alanine load revealed a normal glucagon secretion pattern, whereas the BRB, a boy, was born at term On February 16, l Y 7 j , after a insulin secretion was inappropriately strong. The insulin re-normal Pregnancy. Birthweight was 2800 g, length 48 cm, and sponse to glucagon, however, was subnormal. The alanine load the neonatal period was uneventful. b he ~a t i e n t has two sisters, caused a paradoxic drop in plasma pyruvate. Serial determina-One of whom suffered from hypoglycemia from the age of 2 tions of the fasting values of plasma alanine and free fatty acids months. the and the @FA) disclosed a highly significant negative correlation. had suffered from hypoglycemia. The sister and the mother The best therapeutic effect was obtained with long acting recovered s~ontaneously at 4-5 years of age, and are now in glucagon sc twice daily, but hypoglycemia before the next good health, except that the sister is slightly mentally retarded. injection of glucagon could not be avoided. Glucagon treatment Studies of the other members were refused. caused a marked drop in the plasma amino acids, including the The patient first experienced symptoms of hypoglycemia at branched-chained, and a highly significant decrease in plasma 4.5 months of age, when he got attacks with loss of tonus, eyetriglycerides and increase in FFA, whereas glycerol did not rolling, smacking of the lips, and, occasionally, convulsions. H e change. Dipheuylhydantoin caused a significant increase in Was first admitted to our hospital at 7 months of age, with a blood glucose, but therapeutic serum levels of the drug were glucose of 0.83 mmol/liter. Routine laboratory difficult to achieve. investigations were normal, except for moderate elevations of ~~~i~~ glucagon treatment an oral glucose tolerance test was alanine aminotransferase and aspartate aminotransferase in senormal, with a normal increase in insulin, whereas an iv glucose rum. These values later normalized, but intermittently alanine tolerance test was diabetic (KG = 1.0), and there was n o rise in aminotransferase, alkaline phosphatase, and y-glutam~l transinsulin.
peptidase were elevated. The liver was not enlarged, and It is concluded that the reduced in viva incorporation of 1 4~ appeared normal by laparotomy for liver biopsy. ~i s t o l o~i c a l l~, into glucose from alanine reflected a reduced gluconeogenesis, there was abundant cytoplasmic glycogen, unevenly distributed; and it is proposed that the reduced glucoueogeuesis is a main the liver was EEG was contributor to hypoglycemia in hyperinsulinism. Inappropriately high fasting insulin values compared with the blood glucose values were found (Table 2) (35) and the insulin response to alanine was abnormally strong (Fig. 2) . The hypoSpeculation glycemia was consequently judged to be caused by hypersecreIn most in viva systems changes in insulin concentrations are tion of insulin. The disorder was difficult to treat. Diphenylhyassociated with changes in glucagon, making it difficult to dantoin caused a significant rise in the mean glucose values, but discern the pure effects of insulin. In the presented patient a the patient was still hypoglycemic ( Table 1) . The most effective normal glncagon secretion was faced with an inappropriately increase in blood glucose was achieved with zinc protamine high insulin secretion, providing information about pure insulin glucagon, 0.1 mg/kg body wt sc twice daily (Table 1 , Fig. 1 ). effects.
However, asymptomatic hypoglycemia was registered the last few hours before the next injection of glucagon (Fig. 1 ). This drop in blood glucose could not be overcome, either by increasHyperinsulinism is the most common cause of recurrent ing the frequency of injections, or by increasing the dose of hypoglycemia in infants under 1 year of age (35) . It is generally glucagon. The increased blood glucose values were reflected in acknowledged that this hypoglycemia is caused by increased a reduced frequency of symptomatic hypoglycemic attacks, and peripheral glucose utilization combined with a decreased hepatic the mental and motor development improved. On discharge the glucose production. The suppressive effect of insulin on hepatic condition was fairly well controlled by supplemental glucose, glycogenolysis is well known (1, 17) . An inhibitory action on diphenylhydantoin, and zinc protamine glucagon. gluconeogenesis is also well established in animals (5, 14, 25) .
A t 2 years of age the mental and motor development was Insulin deficiency in animals and man is associated with an moderately retarded. Physically, the patient was small (2.5 perincreased gluconeogenesis, which is normalized by insulin treat-centile), but with normal proportions. The bone age was slightly ment (9, 41) . The effect of insulin hypersecretion on gluconeo-retarded, and the face appeared round and moon shaped. Number of registration periods.
MATERIALS AND METHODS
All investigations, in the patient as well as in the control subjects, were performed with the parents' consent. The ethical aspects of isotope studies have been discussed in a previous publication (37 Plasma was obtained from heparinized venous blood immediately put into an ice bath and separated at 4'. Trasylol was added to blood intended for glucagon analysis. Blood glucose was determined by the ortho-toluidine method ( l a ) , plasma alanine and pyruvate were analyzed microfluorometrically (19) , and FFA, glycerol, and plasma triglycerides according to the "Biochemica Test Combination" (Boehringer, Mannheim, West Germanv) .
, , Amino acids in plasma were determined with a conventional ion exchange procedure at the Department of Clinical Chemistry, Rikshospitalet, Oslo, and diphenylhydantoin in serum by gas-liquid chromatography at the National Epilepsy Centre, Sandvika, Norway.
The alanine tolerance test was performed by injecting 0.25 g L-alaninelkg body wt iv for 1-2 min as a 10% solution. The results were compared with the results of the same test performed in six patients (from 7 months to 3.5 years of age) with hypoglycemia, in whom disorders of insulin and glucagon secretion had been excluded.
The standard glucagon tolerance test was performed by injecting 0.02 mg short acting glucagon/kg body wt rapidly iv, the oral glucose tolerance test by giving 1.75 g, 2 g, or 2.5 g glucose/ kg, and the iv glucose tolerance test by injection of 0.5 g glucose/kg. The tests were done in the morning and the fasting periods were 6-8 hr, according to the patient's tolerance of fasting.
ANALYSES OF HORMONES
Plasma immunoreactive pancreatic glucagon was determined in triplicate according to the method of Heding (16) with the pancreas glucagon specific antiserum K 964 from Novo Research Institute, Denmark, which also supplied us with glucagon for standards and [1251]glucagon. Nonspecific plasma interference with the assay was tested for as described by Weir (42) . Immunoreactive insulin was determined by the double antibody method (15) with kits from the Radiochemical Centre, Amersham. 17-Hydroxycorticosteroids and growth hormone were determined at the Division of Endocrinology, Medical Department B , and thyroxin at the Department of Clinical Chemistry, Rikshospitalet, Oslo.
ASSAY OF GLUCONEOGENESIS
The in vivo method employed is based upon the appearance of radioactivity in glucose after iv injection of trace amounts of [14C]alanine (5 &i/kg body wt). Plasma was analyzed for the amount of radioactivity in alanine, lactate, and glucose by thin layer chromatography. The results are presented as percentages of the total amount of [14C]alanine injected, taking different distribution volumes into account. The appearance of [14C] glucose was used as an index of the overall in vivo gluconeogenesis. The results in four normoglycemic patients used as control subjects and details of the method have been published previously (37) .
The four key enzymes of gluconeogenesis were analyzed in a liver specimen obtained by an open liver biopsy. The liver was immediately frozen and stored in liquid N,. Before the biopsy the patient had been fasted for 8 hr, but during the operation he received 5 % glucose as a continuous iv drip. The human control specimen was obtained from the liver of a 2-year-old boy operated on for a hepatoma. Livers from Wistar rats weighing --f r i m 55 to 173 g werE also used as controls. Glucose-6-phosphatase, fructose-1,6-diphosphatase, phosphoenolpyruvate carboxykinase (PEPCK), pyruvate carboxylase (PC), and glutamic dehydrogenase (GDH) were assayed as previously described (39) . G D H was assayed as a mitochondrial marker. For correction of mitochondrial leakage the following formula was used:
, where E, = corrected extramitochondrial activity in percentage, E, = uncorrected extramitochondrial activity in percentage, and L = percentage of mitochondrial leakage as determined by the G D H determinations.
STATISTICS
The level of significance was calculated using Student's t-test for two means, or the paired t-test, as judged appropriate. A P value of 0.05 was chosen as the significance level. The K value for glucose disappearance rate was calculated as described previously (38) . Linear regression was calculated by the method of least squares. T~r n e (hours) Fig. 2 . Changes in plasma alanine, pyruvate, glucose, insulin, and glucagon after the rapid infusion of alanine at zero time. For alanine the increase above baseline values is given (A alanine), whereas the absolute values are given for the other parameters. The patient is compzred with six hypoglycemic control subjects (mean 2 SE).
RESULTS

SECRETION OF HORMONES
glucagon concentrations were normal (35) . The alanine toler: ance test also indicated insulin hypersecretion (Fig. 2) , with an inappropriately high basal insulin value, and an inordinately strong insulin response to stimulation with alanine. Glucagon secretion however, was similar to that of the controls, as was both the increase in plasma alanine and the subsequent disappearance rate. In all the controls, pyruvate increased 2-3 times during the alanine tolerance test. In contrast, blood pyruvate in the patient decreased sharply. Blood glucose increased during the test (Fig. 2) .
The oral glucose tolerance test was performed twice before glucagon treatment was started, with 1.75 g and 2.5 g glucose/ kg body wt. On both occasions the rise in blood glucose was subnormal, from basal levels of 0.78 and 1.0 mmol/liter to maxima of 1 . l l and 2.0 mmol/liter after 30 min, respectively.
Insulin was not measured during these tests. During a glucagon tolerance test blood glucose increased from 1.2 to 3.6 mmol/ liter after 20 min, and insulin rose from 18 to 25 pU/ml after 10 min. During glucagon treatment glucose tolerance tests were performed in the morning before the next injection of glucagon. A load of 2.0 g glucose/kg body wt perorally caused a rise in blood glucose from 1.7 mmol/liter to a maximum of 4.5 mmol/liter at 30 and 60 min, and insulin rose from 54 pU/ml to 104 pU/ml after 60 min. In contrast with the oral glucose tolerance test the iv glucose tolerance test appeared diabetic. Blood glucose increased from 1.8 to 8.6 mmol/liter. The subsequent disappearance rate was slow (KG = 1 .O%/min), and there was essentially no rise in plasma insulin level, which oscillated between 31 and 35 pU/ml.
17-OH-corticosteroids in urine and plasma were normal, as was growth hormone in plasma. Serum thyroxin was low normal.
STUDIES OF GLUCONEOGENESIS
The in vivo study with [I4C]alanine disclosed a severely reduced incorporation of 14C into glucose (Fig. 3) . Nevertheless, the disappearance rate of 14C from alanine was barely reduced, and the appearance of 14C in lactate was similar to that of the control subjects. Mean blood glucose during the study was 1.3 mmol/liter, plasma alanine 365 I*.mol/liter, pyruvate 25 pmol/ liter, and insulin 28 pU/ml. These concentrations changed minimally during the study.
Since the [14C]alanine test pointed to a severely reduced gluconeogenesis, the key glueoneogenic liver enzymes were studied. In none were the activities reduced (Tables 3 and 4) . On the contrary, the activity of PEPCK was high ( Table 4 ). The intracellular distribution was normal.
However, the reduced gluconeogenesis was reflected in the glucogenic amino acids, which were generally elevated, especially glutamine and proline (Table 5) . It is of interest to note that serial determinations of the fasting values of alanine were negatively correlated with the FFA values. The correlation was highly significant (r = -0.84, n = 12, P < 0.001).
EFFECTS OF TREATMENT
Diphenylhydantoin has been shown to depress insulin and stimulate glucagon secretion in the golden hamster (36) , and in man hyperinsulinism has been reported to be successfully treated with diphenylhydantoin when other drugs have failed (3). In our I The results in 20 normal children 9 months to 2 years of age published by Soupart (34) .
After 6 months of glucagon treatment. Adult values (27) .
patient diphenylhydantoin resulted in a slight, but significant increase in blood glucose (Table 1) . No effect on plasma insulin o r glucagon values could be disclosed. However, it was difficult to obtain serum values of the drug in the therapeutic range (above 40 p.mol/liter), and the patient was still hypoglycemic.
Treatment with zinc protamine glucagon was tried. Figure 1 shows the blood glucose values during the 24-hr period before glucagon treatment was started, and a typical 24-hr curve during glucagon treatment. Except for glucagon, treatment was unchanged (diphenylhydantoin and extra glucose). The increase in the mean blood glucose values was highly significant (Table 1) . In contrast to the mean glucose values, the rise caused by glucagon treatment in the low fasting glucose values was not statistically significant (Table 2) . Fasting insulin, pyruvate, and glycerol were not changed. Plasma alanine fell significantly, but the most impressive changes were observed in the concentrations of triglycerides and FFA; both the increase in FFA and the decrease in triglycerides were highly significant ( Table 2) . Glucagon treatment caused an average reduction in the plasma amino acids of 40% (Table 5 ). The reduction in proline was most pronounced. The branched-chained amino acids were reduced to the same degree as the other amino acids.
DISCUSSION
A n infant with hypoglycemia caused by hypersecretion of insulin has been described. The observed severe reduction of the in vivo incorporation of 14C from alanine into glucose could result from diversion of label into glycogen, an increased utilization rate of glucose, an increased glucose space, or from a reduced rate of gluconeogenesis.
During acute administration of insulin the flow of substrates may be diverted from glucose synthesis into the synthesis of glycogen (1, 5 , 17) . In the fasting steady state, however, a net synthesis of glycogen will not occur. Insulin administration to fasted animals in fact decreases the incorporation of label into glycogen from gluconeogenic precursors, and the amount of label in glycogen in animals and in man during fasting is minimal REDUCED GLUCONEOGENESIS IN HYPERINSULINISM 623 compared with the amount in glucose (4, 5 , 6 , 14) . In addition, abundant liver glycogen and low blood glucose values, as observed in the patient described, inhibits glycogen synthesis (9, 17) . k n increased utilization rate of glucose could not account for the reduced incorporation of I4C into glucose, since the metabolic flow of label the first minutes after the single injection of a radioactive tracer is unidirectional. In the case of [14C]alanine, the appearance of label in glucose the first 5-10 min reflects mainly gluconeogenesis, whereas the later disappearance of label from glucose reflects mainly the utilization rate (14, 37) . In the patient described the appearance of label in glucose was greatly reduced, whereas the disappearance rate paralleled that of the control subjects (Fig. 3) . A change in glucose space could only account for a very minor part of the reduction. In addition, it has been doubted whether insulin really increases glucose space (47) .
It is thus concluded that the reduced incorporation of I4C into glucose reflected a reduced rate of gluconeogenesis. This reduction was coincident with elevated plasma insulin values, and we infer that the reduced gluconeogenesis was caused by hyperinsulinism, facing a normal secretion of glucagon. In a patient previously described by us, a severely reduced gluconeogenesis was associated with glucagon deficiency and normal insulin secretion (38) .
The question is then: by which mechanism does insulin reduce gluconeogenesis? Alanine is mainly taken up and metabolized by the liver ( l o ) , and insulin might decrease the extraction and transamination of alanine (1 1). However, the close to normal kinetics of [14C]alanine and [14C]lactate do not support this hypothesis. More probably, the conversion of pyruvate to glucose within the liver was inhibited, but this inhibition was not reflected in the in vitro activities of the key gluconeogenic enzymes, which were normal, and the activity of PEPCK was elevated. Insulin has been shown to be able to inhibit PEPCK, but this requires the availability of carbohydrate (33, 45) . The patient was severely glucose deficient, and hypoglycemia probably stimulates the activity of PEPCK (9, 33) .
The in vivo activity of the gluconeogenetic key enzymes might nevertheless be restricted. Insulin decreases the transport of pyruvate into the mitochondria, and of malate and aspartate out of the mitochondria (6, 9, 25, 26) . In turn, the substrates available for P C and PEPCK are decreased and the rate of gluconeogenesis is slowed down. Another mechanism may be that insulin increases the activity of glycolytic enzymes, like pyruvate kinase, the inhibition of which a normally functioning ,gluconeo~enesis is dependent upon. Otherwise, futile cycles are created i t h inhibition of gluconcmgenesis and wastage df energy (13. 43.45) .
Insulin decreases lipolysis, decreasing the supply of acetylCoA and N A D H derived from the breakdown of fat. A reduced level of acetyl-CoA and NADH increases the activity of the pyruvate dehydrogenase complex (7, 28) , and may decrease the in vivo activity of PC, for which enzyme acetyl-CoA is an allosteric activator (24, 28, 40) . The net result of the mechanisms mentioned is that pyruvate is used preferentially for oxidation and fatty acid synthesis rather than for gluconeogene-. sis.
The hyperglycemic action of glucagon faded the last hours before the next injection. We believe that the hyperglycemic action of glucagon mainly reflected increased glycogenolysis, although the effect of glucagon on glycogenolysis has been claimed to be evanescent, lasting for only 30-40 min during continuous infusions of glucagon (12, 32) . An exhaustion of the liver glycogen stores would cause a drop in blood glucose. In addition, glucagon stimulates gluconeogenesis, in this patient reflected by the decreased glucogenic amino acids (9) . In a patient with glucagon deficiency glucagon restored normoglycemia throughout the day (38) .
The branched-chained amino acids are catabolized in muscle and other tissues outside the liver under the influence of insulin (2, 10) . The decrease caused by glucagon treatment was therefore not expected, but may indicate that the peripheral catabolism of these amino acids depends on a normal function of the glucose-alanine cycle. This cycle, transporting amino groups to the liver, is disrupted when gluconeogenesis is impaired and restored by glucagon treatment (1 0). The decreased triglycerides and increased FFA during glucagon treatment pointed to an important effect of glucagon. on lipolysis, thus providing extra energy-yielding substrates and sparing glucose (20, 22, 28, 30) . Additionally, the highly significant inverse correlation between alanine and FFA might point to an essential role of FFA in stimulating gluconeogenesis (14, 28, 44) . Glycerol is mainly metabolized to glucose (37) . The unchanged glycerol values during glucagon treatment might therefore reflect that an increased gluconeogenesis compensated for the increased lipolysis.
The insulin secretion response varied with different insulin secretagogues. The response to stimulation with alanine was excessive, the response to glucose per orally was normal, the response to glucagon was subnormal, and the response to glucose iv was virtually zero. This insulin secretion pattern was believed to be indicative of a disturbed pancreatic B cell regulation (29) .
The alanine tolerance test caused a paradoxic decrease in the pyruvate concentrations (Fig. 2) . We observed a similar response in a patient with glucagon deficiency (38) (unpublished data). The insulin response in these patients was exaggerated or unopposed, causing decreased transamination of alanine, increased pyruvate decarboxylation, and perhaps increased disposal of alanine for protein synthesis (2, 9, 10). Blood glucose increased in the patient with hyperinsulinism, but decreased in the patient with glucagon deficiency. This finding is consistent with the concept that the changes in blood glucose after an alanine load mainly reflects glucagon secretion (46) . The Mauriac syndrome is characterized by hepatomegaly with slightly disturbed liver function, dwarfism, moon-shaped face, and cushingoid fat deposition, and is probably caused by the inappropriate administration of short acting insulin in diabetes (21, 23) . Some of these features were recognized in the presented patient. In addition, liver affection was observed in a child subjected to malicious insulin administration (8) . We suggest that similar affections may be caused by endogenous hyperinsulinism.
Finally, we conclude that gluconeogenesis is severely reduced in hyperinsulinism, and we propose that the reduced gluconeogenesis is a main contributor to the hypoglycemia of this disorder.
